162 related articles for article (PubMed ID: 7614473)
1. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RI.
Mamalaki A; Gritzapis AD; Kretsovali A; Belimezi M; Papamatheakis J; Perez SA; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Aug; 52(8):513-22. PubMed ID: 12715240
[TBL] [Abstract][Full Text] [Related]
3. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
[TBL] [Abstract][Full Text] [Related]
4. Genetic Modification of Tumor-Infiltrating Lymphocytes
Weinstein-Marom H; Gross G; Levi M; Brayer H; Schachter J; Itzhaki O; Besser MJ
Front Immunol; 2020; 11():584148. PubMed ID: 33488585
[TBL] [Abstract][Full Text] [Related]
5. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.
Zhao Y; Wang QJ; Yang S; Kochenderfer JN; Zheng Z; Zhong X; Sadelain M; Eshhar Z; Rosenberg SA; Morgan RA
J Immunol; 2009 Nov; 183(9):5563-74. PubMed ID: 19843940
[TBL] [Abstract][Full Text] [Related]
6. Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas.
Halapi E; Yamamoto Y; Juhlin C; Jeddi-Tehrani M; Grunewald J; Andersson R; Hising C; Masucci G; Mellstedt H; Kiessling R
Cancer Immunol Immunother; 1993; 36(3):191-7. PubMed ID: 8439980
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral interleukin-2 immunotherapy: activation of tumor-infiltrating and splenic lymphocytes in vivo.
Dubinett SM; Patrone L; Tobias J; Cochran AJ; Wen DR; McBride WH
Cancer Immunol Immunother; 1993; 36(3):156-62. PubMed ID: 8382559
[TBL] [Abstract][Full Text] [Related]
8. Characterization of tumor-necrosis-factor-gene-transduced tumor-infiltrating lymphocytes from ascitic fluid of cancer patients: analysis of cytolytic activity, growth rate, adhesion molecule expression and cytokine production.
Itoh Y; Koshita Y; Takahashi M; Watanabe N; Kohgo Y; Niitsu Y
Cancer Immunol Immunother; 1995 Feb; 40(2):95-102. PubMed ID: 7882388
[TBL] [Abstract][Full Text] [Related]
9. Retrovirus-mediated gene transfer into CD4+ and CD8+ human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cells.
Morecki S; Karson E; Cornetta K; Kasid A; Aebersold P; Blaese RM; Anderson WF; Rosenberg SA
Cancer Immunol Immunother; 1991; 32(6):342-52. PubMed ID: 2007247
[TBL] [Abstract][Full Text] [Related]
10. Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade.
Palmer DC; Webber BR; Patel Y; Johnson MJ; Kariya CM; Lahr WS; Parkhurst MR; Gartner JJ; Prickett TD; Lowery FJ; Kishton RJ; Gurusamy D; Franco Z; Vodnala SK; Diers MD; Wolf NK; Slipek NJ; McKenna DH; Sumstad D; Viney L; Henley T; Bürckstümmer T; Baker O; Hu Y; Yan C; Meerzaman D; Padhan K; Lo W; Malekzadeh P; Jia L; Deniger DC; Patel SJ; Robbins PF; McIvor RS; Choudhry M; Rosenberg SA; Moriarity BS; Restifo NP
Med; 2022 Oct; 3(10):682-704.e8. PubMed ID: 36007524
[TBL] [Abstract][Full Text] [Related]
11. Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes.
Kalaitsidou M; Moon OR; Sykorova M; Bao L; Qu Y; Sukumaran S; Valentine M; Zhou X; Pandey V; Foos K; Medvedev S; Powell DJ; Udyavar A; Gschweng E; Rodriguez R; Dudley ME; Hawkins RE; Kueberuwa G; Bridgeman JS
Front Immunol; 2023; 14():1256491. PubMed ID: 38022678
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of tumor-targeted IL2 in LTalpha(-/-) mice depends on conditioned T cells.
Schrama D; Voigt H; Eggert AO; Xiang R; Reisfeld RA; Becker JC
Cancer Immunol Immunother; 2006 Jul; 55(7):861-6. PubMed ID: 16158274
[TBL] [Abstract][Full Text] [Related]
13. Genetic Modification of Tumor-Infiltrating Lymphocytes, Peripheral T Cells, and T-Cell Model Cell Lines.
Weinstein-Marom H; Blokon-Kogan D; Levi-Mann M; Katzman C; Shalev S; Zaitsev M; Besser MJ; Shapira-Frommer R; Gross G; Itzhaki O; Nissim L
Methods Mol Biol; 2024; 2748():167-186. PubMed ID: 38070115
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific T-bodies: towards clinical application.
Eshhar Z
Cancer Immunol Immunother; 1997; 45(3-4):131-6. PubMed ID: 9435856
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of multiclonal tumoricidal T cells derived from tumor infiltrating lymphocyte-1derived iPS cells.
Ito T; Kawai Y; Yasui Y; Iriguchi S; Minagawa A; Ishii T; Miyoshi H; Taketo MM; Kawada K; Obama K; Sakai Y; Kaneko S
Commun Biol; 2021 Jun; 4(1):694. PubMed ID: 34099861
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report.
Bubeník J; Perlmann P; Indrová M; Símová J; Jandlová T; Neuwirt J
Cancer Immunol Immunother; 1983; 14(3):205-6. PubMed ID: 6601512
[TBL] [Abstract][Full Text] [Related]
17. Suppression of in vivo tumor growth by the transfection of the interleukin-5 gene into colon tumor cells.
Masuda Y; Mita S; Sakamoto K; Ishiko T; Ogawa M
Cancer Immunol Immunother; 1995 Dec; 41(6):325-30. PubMed ID: 8635189
[TBL] [Abstract][Full Text] [Related]
18. 8th Annual Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015--May 20-22, Vancouver, Canada.
Boudreau JE; Wouters MC; Krawczyk CM
Cancer Immunol Immunother; 2016 Feb; 65(2):235-41. PubMed ID: 26759005
[No Abstract] [Full Text] [Related]
19. Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells.
Karagiannis SN; Bracher MG; Beavil RL; Beavil AJ; Hunt J; McCloskey N; Thompson RG; East N; Burke F; Sutton BJ; Dombrowicz D; Balkwill FR; Gould HJ
Cancer Immunol Immunother; 2008 Feb; 57(2):247-63. PubMed ID: 17657488
[TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.
Pinthus JH; Waks T; Malina V; Kaufman-Francis K; Harmelin A; Aizenberg I; Kanety H; Ramon J; Eshhar Z
J Clin Invest; 2004 Dec; 114(12):1774-81. PubMed ID: 15599402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
